LZHG-2403

N/A

Report date: 2025/08/19 17:09:46
NME

Base Information

Drug NameLZHG-2403
Drug Alias NameLZHG2403LZHG-2403
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionDopamine D2 receptor antagonistsDopamine D3 receptor antagonistsSerotonin 2a (5-HT2a) receptor antagonists
TargetsDopamine D2 receptorDopamine D3 receptorSerotonin 2a (5-HT2a) receptor
Therapy Area/IndicationsSchizophrenia
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaPhase 2 Clinical
Originator CompaniesLivzon Pharmaceutical Group Inc
China Registration ClassN/A

Develop Information

Active CompaniesLivzon Pharmaceutical Group Inc
Inactive CompaniesN/A
Active IndicationsSchizophrenia
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A